Skip to main content

Pharmaceutical Quality Control

  • January 17, 2024

    Addressing Challenges in Expanding Access to Cell & Gene Therapies

    Cell and gene therapies have been undergoing exciting developments recently, including expansion into second line use for existing products. This means that cell and gene therapies are no longer treatments of last resort, and studies are currently underway for front line use.
  • January 03, 2024

    Collaborative Research and Quality Control Supports Cell & Gene Therapy Development & Manufacturing

    The landscape of advanced therapy medicinal products (ATMPs) continues to evolve rapidly, revolutionizing modern medicine to help provide additional treatment options for patients with rare diseases, cancers, and autoimmune disorders.
  • December 20, 2023

    Evolution of Cell and Gene Therapies and the Role of Rapid Quality Control Solutions to Ensure Safe and Effective Products

    Cell, gene, and tissue-based therapies, also referred to as Advanced Therapy Medicinal Products (ATMPs), present unique opportunities to address some of the most problematic diseases, like cancer autoimmune diseases, cardiac diseases, etc., including those with limited treatment options and genetic disorders such as cystic fibrosis, thalassemia, hemophilia, and sickle cell disease.
  • October 25, 2023

    Advanced Therapy Medicinal Products (ATMPs): A Paradigm Shift in Healthcare

    Parkinson’s disease, diabetes, muscular dystrophy: these diseases all lack cures, but they also share another important similarity: the quest for their cures is playing out in the field of ATMPs.
  • October 11, 2023

    Unlocking the potential of pharmaceutical production whilst elevating patient safety

    Scientific discoveries, however important, are not enough to improve public health. Manufacturing infrastructure and innovation are needed to allow pharmaceutical companies to successfully and safely produce products at scale and make them available to clinicians and their patients.